Drug Profile
Research programme: mesenchymal stromal cell therapy - Orbsen Therapeutics
Alternative Names: CD362+ stem cell therapy; CD362+SSC; Cyndacel-M; Cyndecel; ORB1+ MSC; ORB1+ SSCLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Orbsen Therapeutics
- Developer Orbsen Therapeutics; Regenerative Medicine Institute
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
- No development reported Adult respiratory distress syndrome; Diabetic foot ulcer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in Ireland (IV)
- 28 Apr 2021 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in Ireland (Topical, Gel)
- 09 Sep 2020 Preclinical trials in Autoimmune disorders in Ireland (Parenteral) before September 2020 (Orbsen Therapeutics pipeline, September 2020)